Apelin, a promising target for Alzheimer disease prevention and treatment
J Masoumi, M Abbasloui, R Parvan… - Neuropeptides, 2018 - Elsevier
Alzheimer's disease (AD) is a progressive neurodegenerative disease with high outbreak
rates. It is estimated that about 35 million individuals around the world suffered from
dementia in 2010. AD is expected to increase twofold every 20 years and, by 2030,
approximately 65 million people could suffer from this illness. AD is determined clinically by
a cognitive impairment and pathologically by the production of amyloid beta (Aβ),
neurofibrillary tangles, toxic free radicals and inflammatory mediators in the brain. There is …
rates. It is estimated that about 35 million individuals around the world suffered from
dementia in 2010. AD is expected to increase twofold every 20 years and, by 2030,
approximately 65 million people could suffer from this illness. AD is determined clinically by
a cognitive impairment and pathologically by the production of amyloid beta (Aβ),
neurofibrillary tangles, toxic free radicals and inflammatory mediators in the brain. There is …